Search research articles
Contact Us
Filters
Showing results (91-100 of 109) with videos related to
Page
of 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
Gynecologic Oncology
|
October 13, 2021
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer
G E Konecny, A E Wahner Hendrickson, T M Davidson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
G N Hortobagyi, A Lacko, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N Harbeck, P Rastogi, M Martin, et al.
British Journal of Cancer
|
August 2, 2012
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
G C Wishart, C D Bajdik, E Dicks, et al.
Breast (Edinburgh, Scotland)
|
January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients
C C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde
|
January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
P A Fasching, T Fehm, S Kellner, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 109) with videos related to
Sort By:
Page
of 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
Gynecologic Oncology
|
October 13, 2021
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer
G E Konecny, A E Wahner Hendrickson, T M Davidson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
G N Hortobagyi, A Lacko, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N Harbeck, P Rastogi, M Martin, et al.
British Journal of Cancer
|
August 2, 2012
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
G C Wishart, C D Bajdik, E Dicks, et al.
Breast (Edinburgh, Scotland)
|
January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients
C C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde
|
January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
P A Fasching, T Fehm, S Kellner, et al.
Page
of 11